Amicus Therapeutics Discloses Preliminary 2025 Financials Ahead of BioMarin Acquisition

summarizeSummary

Amicus Therapeutics released preliminary unaudited financial results for 2025, reporting approximately $634 million in total net product revenues and $294 million in cash, cash equivalents, and marketable securities, provided in connection with the pending acquisition by BioMarin Pharmaceutical Inc.

check_boxKey Events

• Preliminary 2025 Financials Disclosed

  Amicus Therapeutics provided preliminary unaudited financial information for the year ended December 31, 2025, in connection with its proposed acquisition by BioMarin Pharmaceutical Inc.

• Strong Revenue Performance

  The company estimates total net product revenues of approximately $634 million for 2025, including $522 million from Galafold® and $112 million from Pombiliti® + Opfolda®.

• Solid Cash Position

  As of December 31, 2025, Amicus estimates it had approximately $294 million in cash, cash equivalents, and marketable securities.

• Supports Acquisition Financing

  These financial estimates were provided to BioMarin Pharmaceutical Inc. for inclusion in its preliminary offering memorandum related to a proposed private placement of senior notes to fund the acquisition.

auto_awesomeAnalysis

This 8-K provides preliminary, unaudited financial results for the full year 2025, including strong product revenues and a solid cash position. These figures were provided to BioMarin Pharmaceutical Inc. to support its proposed private placement of senior notes, which will fund the previously announced acquisition of Amicus Therapeutics. The disclosure offers investors a timely look at the company's performance leading into the merger, reinforcing the financial health of the target company. While these are estimates and subject to change, they offer positive context for the ongoing acquisition process.